Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.

Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.

Catch up on the top stories in optometry during the week of May 26-May 30.

Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1310 nm that can scan at a speed of 50,000 A-scan/second.

The partnership aims to accelerate Pangaea’s efforts to address critical care gaps in eye health and systemic disease.

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.

Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, ponders about what she would like to see develop as both a researcher and a clinician in the dry eye space.

In this Q&A, John D. Gelles, OD, and Steven Greenstein, MD, chat about what inspired them to launch the symposium, what makes this year’s agenda especially exciting, and why the future of refractive care depends on stronger collaboration between ODs and MDs.

Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, details the key takeaways from a poster presentation she participated in during ARVO 2025.

deepeye TPS is designed to close the gap between real-world outcomes and trial data by reducing patient dropout.

Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, discussed research that utilized IQVIA longitudinal prescription claims data from September through November 2023, coinciding with Miebo's FDA approval in September.

New data from North American and Chinese clinical trials reinforce the safety, efficacy, and durability of DOT lenses in slowing pediatric myopia progression, without evidence of rebound.

Researchers included 98 phase 2-4 uveitis trials during the time period from clinicaltrials.gov.